Geode Capital Management LLC Grows Position in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Geode Capital Management LLC increased its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 85.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 338,192 shares of the company’s stock after purchasing an additional 155,337 shares during the period. Geode Capital Management LLC owned approximately 0.77% of Xilio Therapeutics worth $266,000 at the end of the most recent quarter.

Separately, XTX Topco Ltd purchased a new position in shares of Xilio Therapeutics during the 2nd quarter worth about $32,000. 54.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Raymond James lowered their price objective on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

Xilio Therapeutics Price Performance

Xilio Therapeutics stock opened at $1.10 on Tuesday. The stock has a market cap of $48.35 million, a price-to-earnings ratio of -0.64 and a beta of -0.25. Xilio Therapeutics, Inc. has a 1 year low of $0.50 and a 1 year high of $1.93. The firm has a 50-day moving average of $1.04 and a two-hundred day moving average of $0.94.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.